Updated Overall Survival Analysis From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer

By afschroeder • October 20, 2025

Johnson ML, Smit EF, Felip E, Ramalingam SS, Ahn MJ, Tsao A, Johnson BE, Offin M, Hussein M, Dagogo-Jack I, Goldman JW, Clarke JM, Negrao MV, Sanborn RE, Morgensztern D, Usari T, Wilner K, Alejandro L, Rifi N, Zhang X, Riely GJ. Updated Overall Survival Analysis From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer. J Clin Oncol. 2025 Oct 19:101200JCO2502023. doi: 10.1200/JCO-25-02023. Epub ahead of print. PMID: 41109959.

Tags: binimetinib, BRAF, Encorafenib, Hematology/Oncology, Non-small cell lung cancer, Publications

Genomic and Transcriptomic Profiling of Radiation-Resistant, Locally Recurrent Prostate Cancer

Neilsen BK, Huang RR, Valle LF, Proudfoot JA, Davicioni E, Zhang L, Ryg U, Schulz-Jaavall M, Weidhaas JB, Santoso M, Parmisano S, Calais J, Reiter[...]

Immune Checkpoint Inhibitor Myocarditis Masquerading as Brugada Syndrome

Talishinsky A, Bachour K, Lin C, Zakka P, Bassam K, Bull L, Garon E, Krokhaleva Y, Hanna P, Yang EH. Immune Checkpoint Inhibitor Myocarditis Masquerading[...]

Domvanalimab and zimberelimab in advanced gastric, gastroesophageal junction or esophageal cancer: a phase 2 trial

Janjigian YY, Oh DY, Pelster M, Wainberg ZA, Prusty S, Nelson S, DuPage A, Thompson A, Koralek DO, Sison EAR, Rha SY. Domvanalimab and zimberelimab[...]